Difference between revisions of "Umbralisib (Ukoniq)"
Jump to navigation
Jump to search
m |
m |
||
| Line 28: | Line 28: | ||
[[Category:Marginal zone lymphoma medications (historic)]] | [[Category:Marginal zone lymphoma medications (historic)]] | ||
[[Category:FDA approved in 2021]] | [[Category:FDA approved in 2021]] | ||
| + | |||
| + | [[Category:Discontinued drugs]] | ||
[[Category:FDA withdrawn in 2022]] | [[Category:FDA withdrawn in 2022]] | ||
[[Category:TG Therapeutics compound]] | [[Category:TG Therapeutics compound]] | ||
Revision as of 01:43, 2 June 2022
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it was used
Patient Drug Information
History of changes in FDA indication
- 2/5/2021: Accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. (Based on UNITY-NHL)
- 2/5/2021: Accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. (Based on UNITY-NHL)
- 6/1/2022: Withdrawn due to safety concerns. (Based on UNITY-CLL)
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq